Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950945 · ClinicalTrials.gov registry record · Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT05950945 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 250 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05950945, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
Other
- GenesisCare St Andrews Hospital - Adelaide
- Fiona Stanley Hospital - Murdoch
- Institut Jules Bordet - Anderlecht
- GZA Ziekenhuizen - Antwerp
- Universitair Ziekenhuis Brussel - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- UZ Leuven - Leuven
- Centre Hospitalier Universitaire de Liege Sart-Tilman - Liège
- GZA Ziekenhuizen - Wilrijk
- Centro de Oncologia - Unidade Brasília - Hospital Sírio Libanês - Brasília
- CIONC-Centro Integrado de Oncologia de Curitiba - Curitiba
- Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer - Curitiba
- CEPON - Centro de Pesquisas Oncológicas de Santa Catarina - Florianópolis
Florida
- Mount Sinai Medical Center - Miami Beach
- USF College of Medicine - Tampa
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Beth Israel Lahey Health - Burlington
New Jersey
- Overlook Medical Center - Summit
New South Wales
- Mater Hospital Sydney - North Sydney
Victoria
- Monash Medical Centre Moorabbin - East Bentleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-12-30 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05950945
The ClinicalTrials.gov registry entry for NCT05950945 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab Deruxtecan is the first listed.
NCT05950945 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05950945 about?
NCT05950945 is a clinical study titled "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer". This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cance...
What is the current status of trial NCT05950945?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2023-12-30. Estimated completion is 2027-10-01.
What conditions does trial NCT05950945 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05950945?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05950945?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05950945 being conducted?
This trial has 20 study locations across Florida, Massachusetts, New Jersey, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.